Cover Image
市場調查報告書

ElexoPharm GmbH:產品平台分析

ElexoPharm GmbH - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 307845
出版日期 內容資訊 英文 24 Pages
訂單完成後即時交付
價格
Back to Top
ElexoPharm GmbH:產品平台分析 ElexoPharm GmbH - Product Pipeline Review - 2015
出版日期: 2015年02月24日 內容資訊: 英文 24 Pages
簡介

ElexoPharm GmbH 是提供針對內分泌系統疾病之前臨床階段獨家研究計劃的生物製藥公司,提供醫藥品化學領域的調查服務。其服務項目有諮詢、研究合作、合理的藥物設計、潛力化合物的最佳化、新的先導化合物、開發新藥流程、新的生物學標的檢驗、經濟風險的最小化等。還有該公司的研究開發部門,正致力於活用人類用的治療方法來設計及開發藥物。

本報告提供ElexoPharm GmbH的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

ElexoPharm GmbH的基本資料

  • ElexoPharm GmbH概要
  • 主要資訊
  • 企業資料

ElexoPharm GmbH :R&D概要

  • 主要的治療範圍

ElexoPharm GmbH :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

ElexoPharm GmbH :開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

ElexoPharm GmbH :藥物簡介

  • Small Molecule to Inhibit CYP11B1 for Cushing's Disease and Subclinical Hypercortisolism
  • Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis
  • Small Molecules to Inhibit 17Beta-HSD2 for Osteoporosis
  • Eurostars Program

ElexoPharm GmbH :開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

ElexoPharm GmbH :總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06802CDB

Summary

Global Markets Direct's, 'ElexoPharm GmbH - Product Pipeline Review - 2015', provides an overview of the ElexoPharm GmbH's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ElexoPharm GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of ElexoPharm GmbH including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of ElexoPharm GmbH's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the ElexoPharm GmbH's pipeline products

Reasons to buy

  • Evaluate ElexoPharm GmbH's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of ElexoPharm GmbH in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the ElexoPharm GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of ElexoPharm GmbH and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of ElexoPharm GmbH
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of ElexoPharm GmbH and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • ElexoPharm GmbH Snapshot
    • ElexoPharm GmbH Overview
    • Key Information
    • Key Facts
  • ElexoPharm GmbH - Research and Development Overview
    • Key Therapeutic Areas
  • ElexoPharm GmbH - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • ElexoPharm GmbH - Pipeline Products Glance
    • ElexoPharm GmbH - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • ElexoPharm GmbH - Drug Profiles
    • Small Molecule to Inhibit CYP11B1 for Cushing's Disease and Subclinical Hypercortisolism
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit 17Beta-HSD2 for Osteoporosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Eurostars Program
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • ElexoPharm GmbH - Pipeline Analysis
    • ElexoPharm GmbH - Pipeline Products by Target
    • ElexoPharm GmbH - Pipeline Products by Molecule Type
    • ElexoPharm GmbH - Pipeline Products by Mechanism of Action
  • ElexoPharm GmbH - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • ElexoPharm GmbH, Key Information
  • ElexoPharm GmbH, Key Facts
  • ElexoPharm GmbH - Pipeline by Indication, 2015
  • ElexoPharm GmbH - Pipeline by Stage of Development, 2015
  • ElexoPharm GmbH - Monotherapy Products in Pipeline, 2015
  • ElexoPharm GmbH - Partnered Products in Pipeline, 2015
  • ElexoPharm GmbH - Partnered Products/ Combination Treatment Modalities, 2015
  • ElexoPharm GmbH - Out-Licensed Products in Pipeline, 2015
  • ElexoPharm GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • ElexoPharm GmbH - Preclinical, 2015
  • ElexoPharm GmbH - Discovery, 2015
  • ElexoPharm GmbH - Pipeline by Target, 2015
  • ElexoPharm GmbH - Pipeline by Molecule Type, 2015
  • ElexoPharm GmbH - Pipeline Products by Mechanism of Action, 2015
  • ElexoPharm GmbH, Other Locations

List of Figures

  • ElexoPharm GmbH - Pipeline by Top 10 Indication, 2015
  • ElexoPharm GmbH - Pipeline by Stage of Development, 2015
  • ElexoPharm GmbH - Monotherapy Products in Pipeline, 2015
  • ElexoPharm GmbH - Pipeline by Top 10 Target, 2015
  • ElexoPharm GmbH - Pipeline by Top 10 Molecule Type, 2015
  • ElexoPharm GmbH - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top